Ovid Therapeutics Inc. (OVID) Ownership
OVID ownership summary
as of October 18, 2026- Institutions
- 80.4% of shares outstanding
- Insiders
- 6.72% of shares outstanding
- Shares outstanding
- 195.3M
- Float
- 163.4M shares available to trade
- Short interest
- 11.11% 18.9M shares short
- Days to cover
- 11.15 short interest down 10.4% vs prior month
- Institutions 80.42%
- Insiders 6.72%
- Other investors 12.86%
OVID top institutional holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Jupiter Topco LLC | 10.62% | 20.7M | $44.6M | +20.7M (0.0%) | June 30, 2026 |
| 2 | Eventide Asset Management, LLC | 6.05% | 11.8M | $25.4M | +1.9M (+19.1%) | June 30, 2026 |
| 3 | BlackRock Inc | 5.54% | 10.8M | $23.3M | +9.3M (+605.9%) | June 30, 2026 |
| 4 | HHG PLC | 5.49% | 10.7M | $23.0M | +10.7M (0.0%) | March 31, 2026 |
| 5 | RA Capital Management, LLC | 5.38% | 10.5M | $22.6M | −213,032 (−2.0%) | June 30, 2026 |
| 6 | Affinity Asset Advisors, LLC | 5.19% | 10.1M | $21.8M | −491,756 (−4.6%) | June 30, 2026 |
| 7 | State Street Corp | 4.05% | 7.9M | $17.0M | +7.4M (+1,418.6%) | June 30, 2026 |
| 8 | Vanguard Capital Management, LLC | 3.97% | 7.8M | $16.7M | +2.5M (+47.6%) | June 30, 2026 |
| 9 | ADAR1 Capital Management LLC | 3.80% | 7.4M | $15.9M | +2.9M (+63.2%) | June 30, 2026 |
| 10 | Balyasny Asset Management LLC | 3.44% | 6.7M | $14.4M | +1.2M (+21.4%) | June 30, 2026 |
| 11 | Adage Capital Partners Gp LLC | 3.16% | 6.2M | $13.3M | — | June 30, 2026 |
| 12 | Federated Hermes Inc | 3.05% | 6.0M | $12.8M | +2.4M (+66.7%) | June 30, 2026 |
| 13 | BRAIDWELL LP | 3.03% | 5.9M | $12.7M | +5.9M (0.0%) | June 30, 2026 |
| 14 | Geode Capital Management, LLC | 2.09% | 4.1M | $8.8M | +2.8M (+209.0%) | June 30, 2026 |
| 15 | SILVERARC CAPITAL MANAGEMENT, LLC | 1.59% | 3.1M | $6.7M | +2.1M (+210.1%) | June 30, 2026 |
| 16 | StemPoint Capital LP | 1.24% | 2.4M | $5.2M | +2.4M (0.0%) | June 30, 2026 |
| 17 | Ikarian Capital, LLC | 1.16% | 2.3M | $4.9M | −625,000 (−21.6%) | June 30, 2026 |
| 18 | Point72 Asset Management, L.P. | 1.00% | 1.9M | $4.2M | +625,117 (+47.3%) | June 30, 2026 |
| 19 | Sphera Funds Management Ltd. | 0.69% | 1.4M | $2.9M | −269,828 (−16.6%) | June 30, 2026 |
| 20 | Northern Trust Corp | 0.64% | 1.2M | $2.7M | +991,335 (+389.1%) | June 30, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 20, 15 holders added 73.8M shares and 4 cut 1.6M.
OVID top mutual fund and ETF holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Eventide Healthcare & Life Sciences I | 6.05% | 11.8M | $25.4M | +1.9M (+19.1%) | June 30, 2026 |
| 2 | Federated Hermes Kaufmann Small Cap A | 3.05% | 6.0M | $12.8M | +2.4M (+66.7%) | June 30, 2026 |
| 3 | Vanguard MStar Total Stk Mkt Idx Invest | 2.89% | 5.7M | $12.2M | — | August 31, 2026 |
| 4 | iShares Russell 2000 ETF | 2.16% | 4.2M | $9.1M | −48,704 (−1.1%) | September 30, 2026 |
| 5 | State Street® SPDR® S&P® Biotech ETF | 1.43% | 2.8M | $6.0M | −53,400 (−1.9%) | September 30, 2026 |
| 6 | Fidelity Small Cap Index | 0.86% | 1.7M | $3.6M | +14,866 (+0.9%) | July 31, 2026 |
| 7 | iShares Russell 2000 Value ETF | 0.69% | 1.4M | $2.9M | +2,052 (+0.2%) | September 30, 2026 |
| 8 | Vanguard Russell 2000 ETF | 0.49% | 960K | $2.1M | +80,768 (+9.2%) | September 30, 2026 |
| 9 | Fidelity Extended Market Index | 0.43% | 835K | $1.8M | −4,488 (−0.5%) | August 31, 2026 |
| 10 | Biotech Growth Ord | 0.38% | 747K | $1.6M | +385,000 (+106.4%) | June 30, 2026 |
| 11 | Nuveen Equity Index R6 | 0.33% | 647K | $1.4M | — | August 31, 2026 |
| 12 | iShares Micro-Cap ETF | 0.27% | 520K | $1.1M | −3,587 (−0.7%) | September 30, 2026 |
| 13 | Fidelity Enhanced Small Cap Core ETF | 0.26% | 511K | $1.1M | +1,071 (+0.2%) | September 30, 2026 |
| 14 | Schwab Small Cap Index | 0.19% | 372K | $799,852 | — | August 31, 2026 |
| 15 | Fidelity Total Market Index | 0.18% | 348K | $747,940 | — | August 31, 2026 |
| 16 | iShares Core S&P Total US Stock Mkt ETF | 0.18% | 343K | $736,998 | +300 (+0.1%) | September 30, 2026 |
| 17 | iShares Russell 2000 Small-Cap Idx Instl | 0.15% | 286K | $615,403 | — | August 31, 2026 |
| 18 | Fidelity Series Total Market Index | 0.13% | 263K | $565,080 | −12,177 (−4.4%) | August 31, 2026 |
| 19 | Avantis US Small Cap Equity ETF | 0.13% | 256K | $550,282 | +732 (+0.3%) | September 30, 2026 |
| 20 | Stt Strt SPDR® Russell2000 US SmCapETF | 0.11% | 209K | $448,791 | +34,166 (+19.6%) | September 30, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
OVID insider transactions
latest 2| Date | Name | Transaction | Price | Shares | Value |
|---|---|---|---|---|---|
| 2025-01-27 | Margaret A Alexander | Buy | $0.73 | 6,810 | $4,971 |
| 2024-03-18 | Jeremy M Levin | Buy | $2.76 | 18,248 | $50,364 |
Reported trades by company officers, directors and other filers (including disclosures by members of Congress where EODHD lists them). "—" where the filing gives no share count.
OVID shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns OVID
Institutional investors own 80.4% of Ovid Therapeutics's shares and insiders 6.72%. The largest holder is Jupiter Topco LLC with 10.62% of the shares (20.7M), as of June 30, 2026. Among the top 20 institutions, 15 added shares and 4 reduced their stake in the latest filings. Short interest is 11.11% of the float, or 11.15 days of average trading volume. The share count rose 730.3% since 2015.
Related: OVID analyst forecast, OVID key metrics. See the OVID stock overview for the latest quote and news.
OVID ownership FAQ
Who owns the most Ovid Therapeutics stock?
The largest shareholders of Ovid Therapeutics are Jupiter Topco LLC (10.62%), Eventide Asset Management, LLC (6.05%), BlackRock Inc (5.54%), HHG PLC (5.49%), RA Capital Management, LLC (5.38%).
What percentage of Ovid Therapeutics is owned by institutions?
Institutions hold 80.4% of Ovid Therapeutics's shares outstanding; insiders hold 6.72%.
Which funds own Ovid Therapeutics?
The largest fund holders of Ovid Therapeutics are Eventide Healthcare & Life Sciences I (6.05%), Federated Hermes Kaufmann Small Cap A (3.05%), Vanguard MStar Total Stk Mkt Idx Invest (2.89%), iShares Russell 2000 ETF (2.16%), State Street® SPDR® S&P® Biotech ETF (1.43%).
What is Ovid Therapeutics's short interest?
18.9M shares of Ovid Therapeutics were sold short, 11.11% of the float; at the average daily volume it would take 11.15 days to cover.
Are insiders buying or selling Ovid Therapeutics?
Of the latest 2 reported insider transactions in Ovid Therapeutics (since March 18, 2024), 2 were purchases and 0 were sales.
How many shares of Ovid Therapeutics are outstanding?
Ovid Therapeutics has 195.3M shares outstanding, of which 163.4M are in the public float.